231 related articles for article (PubMed ID: 26123313)
1. Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
Nishikawa M; Miyake H; Fujisawa M
Int J Clin Oncol; 2016 Feb; 21(1):162-7. PubMed ID: 26123313
[TBL] [Abstract][Full Text] [Related]
2. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.
Nonomura N; Oka D; Nishimura K; Nakayama M; Inoue H; Mizutani Y; Miki T; Okuyama A
Int J Urol; 2007 Jun; 14(6):527-31. PubMed ID: 17593098
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors.
Shiraishi T; Nakamura T; Mikami K; Takaha N; Kawauchi A; Miki T
Int J Clin Oncol; 2009 Oct; 14(5):436-41. PubMed ID: 19856053
[TBL] [Abstract][Full Text] [Related]
5. [Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer].
Nomoto T; Mizutani Y; Mikami K; Nakamura T; Nakanishi H; Kawauchi A; Miki T
Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):630-5. PubMed ID: 16768143
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemotherapy with docetaxel, ifosfamide and nedaplatin (DIN) for patients with advanced germ cell tumors: a preliminary report.
Yamada S; Saito H; Ohara S; Yamashita S; Mitsuzuka K; Namiki S; Miyazato M; Kaiho Y; Ito A; Nakagawa H; Ishidoya S; Arai Y
Jpn J Clin Oncol; 2013 Jul; 43(7):734-9. PubMed ID: 23619987
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors.
Miki T; Mizutani Y; Nonomura N; Nomoto T; Nakao M; Saiki S; Kotake T; Okuyama A
Cancer; 2002 Nov; 95(9):1879-85. PubMed ID: 12404281
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumors.
Nishikawa M; Miyake H; Muramaki M; Fujisawa M
Med Oncol; 2014 Dec; 31(12):296. PubMed ID: 25341372
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
Farmakis D; Pectasides M; Pectasides D
Eur Urol; 2005 Sep; 48(3):400-7. PubMed ID: 15964136
[TBL] [Abstract][Full Text] [Related]
10. Less nephrotoxicity of paclitaxel and ifosfamide plus nedaplatin for refractory or relapsed germ cell tumors in patients with impaired renal function.
Shiraishi T; Nakamura T; Takamura T; Oishi M; Yamada T; Yamada Y; Ueda T; Fujihara A; Hongo F; Okihara K; Ukimura O
Int J Urol; 2020 Feb; 27(2):134-139. PubMed ID: 31701563
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.
Feldman DR; Hu J; Dorff TB; Lim K; Patil S; Woo KM; Carousso M; Hughes A; Sheinfeld J; Bains M; Daneshmand S; Ketchens C; Bajorin DF; Bosl GJ; Quinn DI; Motzer RJ
J Clin Oncol; 2016 Jul; 34(21):2478-83. PubMed ID: 27185842
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L; Caty A; Soares DG; de Revel T; Fizazi K; Gligorov J; Micléa JM; Dubot C; Provent S; Temby I; Gaulet M; Horn E; Brindel I; Lotz JP
Ann Oncol; 2014 Sep; 25(9):1775-1782. PubMed ID: 24894084
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
[TBL] [Abstract][Full Text] [Related]
15. Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
Narayan V; Gunnarsson O; Hwang WT; Squillante CM; Nathanson KL; Stadtmauer EA; Vaughn DJ
Clin Genitourin Cancer; 2016 Dec; 14(6):524-529. PubMed ID: 27083130
[TBL] [Abstract][Full Text] [Related]
16. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
18. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Fizazi K; Gravis G; Flechon A; Geoffrois L; Chevreau C; Laguerre B; Delva R; Eymard JC; Rolland F; Houede N; Laplanche A; Burcoveanu D; Culine S
Ann Oncol; 2014 May; 25(5):987-91. PubMed ID: 24595454
[TBL] [Abstract][Full Text] [Related]
19. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma.
Harstrick A; Schmoll HJ; Wilke H; Köhne-Wömpner CH; Stahl M; Schöber C; Casper J; Bruderek L; Schmoll E; Bokemeyer C
J Clin Oncol; 1991 Sep; 9(9):1549-55. PubMed ID: 1651992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
